Echo research and practice · 2026
Multi-valvular burden score and one-year mortality in ICU patients undergoing echocardiography: an exploratory cohort study.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Isleyen Hasan Burak, Yavuz Sevil Tugrul, Bulut Sercan, Kizkapan Fatih, Alioglu Cevahir, Sozen Ali Arda, Khanmohammadi Mahsa
Аннотация
BACKGROUND: Multiple regurgitant lesions coexist in critically ill patients, yet cohort-level analyses typically represent each valve separately. We evaluated whether a Multi-Valvular Burden (MVB) score could summarize regurgitant involvement and whether its prognostic information differed from models retaining individual valve grades.
METHODS: This retrospective cohort used MIMIC-IV v3.1 linked with MIMIC-IV-ECHO. Adults with an ICU admission and complete ordinal grading of tricuspid, mitral, and aortic regurgitation on an index echocardiogram within 72 h of ICU admission were included. MVB was the arithmetic sum of TR, MR, and AR grades (0-12). Cox models assessed 1-year all-cause mortality. Additional analyses compared MVB with separate valve-grade models, tested a high-burden definition requiring MVB > = 4 and at least two involved valves, used missing-aware AS/MS evidence proxies, and examined LVEF with structured RV-function classification.
RESULTS: The cohort included 5,362 patients; 1,979 (36.9%) died within 1 year. Mortality increased from 24.6% at MVB 0 to 47.4% at MVB > = 4. After clinical adjustment, continuous MVB remained associated with mortality (HR 1.07 per point, 95% CI 1.05-1.09; P < 0.001), and MVB > = 4 was associated with higher mortality (HR 1.35, 95% CI 1.22-1.48; P < 0.001). The high-burden category predominantly reflected multivalve involvement: 2,206 of 2,257 patients with MVB > = 4 had at least two affected valves. A model with separate TR, MR, and AR grades showed similar discrimination to the MVB model (C-index 0.7585 vs. 0.7582). Incremental discrimination over the clinical model was small (C-index 0.7543 to 0.7582; delta 0.0039), although likelihood-ratio improvement was statistically significant (chi-square 50.61; P < 0.001). MVB remained associated with mortality in the missing-aware AS/MS sensitivity model (HR 1.07, 95% CI 1.05-1.09) and the LVEF/structured RV-function subset (HR 1.05, 95% CI 1.03-1.08).
CONCLUSIONS: MVB is an exploratory summary marker rather than an outcome-derived or mechanistic weighting system. Its near-identical discrimination to a model retaining individual valve grades and very modest incremental discrimination suggest that it is best viewed as a compact descriptive marker of broader cardiovascular burden within systemic critical illness, not as a stand-alone clinical decision tool or evidence of a causal pathway to mortality.
CLINICAL TRIAL NUMBER: Not applicable.
TRIAL REGISTRATION: Not applicable.
METHODS: This retrospective cohort used MIMIC-IV v3.1 linked with MIMIC-IV-ECHO. Adults with an ICU admission and complete ordinal grading of tricuspid, mitral, and aortic regurgitation on an index echocardiogram within 72 h of ICU admission were included. MVB was the arithmetic sum of TR, MR, and AR grades (0-12). Cox models assessed 1-year all-cause mortality. Additional analyses compared MVB with separate valve-grade models, tested a high-burden definition requiring MVB > = 4 and at least two involved valves, used missing-aware AS/MS evidence proxies, and examined LVEF with structured RV-function classification.
RESULTS: The cohort included 5,362 patients; 1,979 (36.9%) died within 1 year. Mortality increased from 24.6% at MVB 0 to 47.4% at MVB > = 4. After clinical adjustment, continuous MVB remained associated with mortality (HR 1.07 per point, 95% CI 1.05-1.09; P < 0.001), and MVB > = 4 was associated with higher mortality (HR 1.35, 95% CI 1.22-1.48; P < 0.001). The high-burden category predominantly reflected multivalve involvement: 2,206 of 2,257 patients with MVB > = 4 had at least two affected valves. A model with separate TR, MR, and AR grades showed similar discrimination to the MVB model (C-index 0.7585 vs. 0.7582). Incremental discrimination over the clinical model was small (C-index 0.7543 to 0.7582; delta 0.0039), although likelihood-ratio improvement was statistically significant (chi-square 50.61; P < 0.001). MVB remained associated with mortality in the missing-aware AS/MS sensitivity model (HR 1.07, 95% CI 1.05-1.09) and the LVEF/structured RV-function subset (HR 1.05, 95% CI 1.03-1.08).
CONCLUSIONS: MVB is an exploratory summary marker rather than an outcome-derived or mechanistic weighting system. Its near-identical discrimination to a model retaining individual valve grades and very modest incremental discrimination suggest that it is best viewed as a compact descriptive marker of broader cardiovascular burden within systemic critical illness, not as a stand-alone clinical decision tool or evidence of a causal pathway to mortality.
CLINICAL TRIAL NUMBER: Not applicable.
TRIAL REGISTRATION: Not applicable.